论文部分内容阅读
目的:观察升降散对大鼠系膜增生性肾小球肾炎的治疗作用,探讨升降散对系膜增生性肾小球肾炎大鼠肾组织CTGF、α-SMA表达的影响。方法:将正常W istar大鼠(50天龄)40只随机分为对照组、模型组、洛汀新组、升降散组。模型组与药物干预组分别制备慢性系膜增生性肾小球肾炎模型。采用免疫组织化学法检测各组肾脏组织中CTGF、α-SMA的表达。结果与对照组大鼠相比,模型组大鼠肾小球系膜区、肾间质CTGF、α-SMA阳性表达明显(P<0.01),两药物组相应区域CTGF、α-SMA均呈弱阳性表达(P<0.05),而两药物组比较差异无明显统计学意义(P>0.05)。结论:升降散能够降低慢性系膜增生性肾小球肾炎大鼠肾组织CTGF及α-SMA表达;减弱肾小球系膜区及肾间质中细胞与基质的增生,减轻肾纤维化的程度。
Objective: To observe the therapeutic effect of Shengjiang San on mesangial proliferative glomerulonephritis in rats and to explore the effect of Shengjiang Powder on the expression of CTGF and α-SMA in renal tissue of rats with mesangial proliferative glomerulonephritis. Methods: Forty normal Wistar rats (50 days old) were randomly divided into control group, model group, Lotensin group and Shengjiangsan group. Model group and drug intervention group were prepared chronic mesangial proliferative glomerulonephritis model. Immunohistochemistry was used to detect the expression of CTGF and α-SMA in each group. Results Compared with the control group, the expression of CTGF and α-SMA in glomerular mesangial area and renal interstitium in model group was significantly higher than that in control group (P <0.01). The CTGF and α-SMA in the two groups were all weak (P <0.05), but there was no significant difference between the two drug groups (P> 0.05). Conclusion: Shengmaosan can reduce the expression of CTGF and α-SMA in renal tissue of rats with chronic mesangial proliferative glomerulonephritis, weaken the proliferation of cells and matrix in mesangial area and renal interstitium, and reduce the degree of renal fibrosis .